Filter announcements
Loading...
Founded in 2019, Asston Pharmaceuticals Limited manufactures and exports pharmaceutical formulations and nutraceuticals under the "Asston" brand, utilizing a diversified business model that includes direct sales, contract manufacturing, and export primarily to African markets.
Asston Pharmaceuticals' Board has approved the allotment of 2.41 Cr equity shares at Rs. 115 each, including a premium of Rs. 105. This preferential issue was made to 15 investors. Following this allotment, the company's paid-up equity share capital has increased to Rs. 10.92 Cr, comprising 1.09 Cr shares of...
The company has announced a board meeting on October 26. The key agenda for this meeting is to review and approve the financial results for the quarter and half-year. This is a crucial update for investors, offering insights into the company's recent operational and financial performance. Additionally, the Board will...
Asston Pharmaceuticals' board has approved several key appointments and resolutions. M/s Yash A. Jain & Associates was appointed as Internal Auditor, while M/s Panchal S K & Associates will serve as Statutory Auditors. The board proposed the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director, subject to member approval....
Asston Pharmaceuticals' board approved key appointments and future plans. M/s Yash A. Jain & Associates was appointed as Internal Auditor, and M/s Panchal S K & Associates as Statutory Auditors. The board also put forward Mr. Ashish Narayan Sakalkar for re-appointment as Managing Director and proposed increased remuneration for him,...
Asston Pharmaceuticals has submitted a compliance certificate for a quarter, received from its Registrar and Share Transfer Agent. This certificate confirms the proper handling of share transfers and dematerialization requests. This update assures investors of the company's adherence to share-related regulatory procedures, ensuring transparency and efficiency in managing its shareholder...